TCT 2020 | Xience in Favor of Short Dual Antiaggregation Therapy with High Bleeding Risk

Following with aspirin alone after a short period of dual antiaggregation therapy (DAPT), 1 to 3 months, did not increase ischemic events in patients receiving a Xience stent while significantly reducing bleeding. 

TCT 2020 | Xience se suma a la evidencia de doble antiagregación corta en alto riesgo de sangrado

This study endorses the safety of short DAPT with contemporary drug eluting stents (DES) in patients presenting high bleeding risk. 

The XIENCE Short DAPT program tested the safety of 1 and 3-month DAPT in 3600 patients. On the one hand, the XIENCE 90 included over 2000 patients receiving 3-month DAPT and on the other hand the XIENCE 28 included 1500 patients receiving only 1- month DAPT. Both studies were prospective, open, non-randomized and compared against historical cohorts. 

All included patients were at high risk of bleeding based on the presence of at least one of the following characteristics: > 75 years, chronic anticoagulation, high bleeding risk within one year of index angioplasty, a history of stroke, kidney failure, coagulation alteration or anemia. 


Read also: TCT 2020 | Acurate Neo Does Not Meet Non-Inferiority vs. CoreValve Evolut.


Patients with ST elevation MI, ejection fraction <30% or with pending surgery in the following months were excluded. 

After index PCI with the XIENCE stent, patients received aspirin with a P2Y12 receptor inhibitor. After 1 or 3 months (depending on the study) they continued with aspirin alone.

Both the XIENCE 90 and the XIENCE 28 showed non-inferiority as regards the primary end point of death or infarction vs. XIENCE V control all-comers.


Read also: TCT 2020 | Crushed Prasugrel Administration prior PCI.


The secondary end point of BARC 2 to 5 bleeding resulted 5.1% with 3-month DAPT vs. 7% of the control patients (p=0.0063 for superiority). The group that received one- month DAPT showed a bleeding rate of 4.9% vs 5.9% in the control group (p=0.19 for superiority).

Major bleeding (BARC 3 to 5) resulted far less frequent in both studies. For the XIENCE 90, major bleeding rate was 2.2% vs 6.3% in the control group (p<0.0001) and for XIENCE 28 of 2.2% vs 4.5% (p=0.0015).

Original Title: The XIENCE Short DAPT Program: XIENCE 90/28 evaluating the safety of 3- and 1-month DAPT in HBR patients.

Reference: Presentado por Roxana Mehran en el congreso TCT 2020 virtual.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....